Background: Homeobox genes A10 (HOXA10) and A11 (HOXA11), members of the abdominal B gene family, are responsible for embryonic survival and implantation. This study was planned to investigate whether endometrial injury alters the expression of both transcripts in women with implantation failure. Methods: A total of 54 women with implantation failure were divided into two equal groups as experimental (scratching) and sham (no scratching). Participants in the scratching group were exposed to endometrial injury in the mid-luteal phase, and those in the sham group were exposed to endometrial flushing. The scratching group, but not the sham group, underwent prior endometrial sampling. A second endometrial sampling was performed on the scratching group in the mid-luteal phase of the following cycle. The mRNA and protein levels of the HOXA10 and 11 transcripts were determined in endometrial samples collected before and after injury/flushing. Participants in each group underwent IVF/ET in the cycle after the second endometrial sampling. Results: Endometrial injury caused a 60.1-fold (p < 0.01) increase in HOXA10 mRNA and a 9.0-fold increase in HOXA11 mRNA (p < 0.02). Injury resulted in a significant increase in both HOXA10 (p < 0.001) and HOXA11 protein expression (p < 0.003). There was no significant change in HOXA10 and 11 mRNA expressions after flushing. Clinical pregnancy, live birth, and miscarriage rates of the both groups were similar. Conclusions: Endometrial injury increases homeobox transcript expression at both mRNA and protein levels.
Objective: Most studies concentrate on comparisons between the cleavage stage and blastocyst stage of embryos during in vitro stimulation treatment. We aimed, in this study, to compare the pregnancy rates of day 4 or day 5 blastocyst transfers, all derived from fresh, antagonist-regulated in vitro fertilization (IVF) cycles, and to evaluate the factors affecting pregnancy success. Methods: This retrospective cohort study evaluated 3681 fresh embryo transfer cycles conducted at a private IVF center between 2019 and 2021. Patients were divided into two groups based on the day of embryo transfer: day 4 (Group 1) and day 5 (Group 2). Subgroup analyses were performed according to age (≤40 vs. >40 years) and the number of oocytes retrieved (≤4 vs. >4). All patients underwent ovarian stimulation with FSH alone or in combination with hMG, and GnRH antagonist protocols were used for pituitary suppression. Final oocyte maturation was triggered with recombinant hCG, and fertilization was achieved via intracytoplasmic sperm injection (ICSI) for all cases. Embryos were cultured in sequential media and assessed daily until transfer on day 4 or day 5, based on embryo morphology and clinic logistics. Results: Pregnancy was more likely among women under 40 than among women over 40. There were a total of 1217 women who underwent day 4 transfer and 2464 women who underwent day 5 transfer. A total of 660 (54.2%) of the women transferred on day 4 developed pregnancy. Among those transferred on day 5, 1610 (65.3%) developed pregnancy. When compared to the 4th day, a single embryo transfer on the 5th day enhances pregnancy success by 1.8 times, while two embryo transfers raise it by 1.6 times. Furthermore, when the number of oocytes is greater than four and the number of embryos transferred is two, the pregnancy success rate is 2.5 times higher when embryo transfer is performed on the fifth day versus the fourth day. Regardless of age, oocyte count, or number of embryos transferred, 5th-day fresh embryo transfers enhanced pregnancy success by 1.9 times compared to 4th-day transfer. Conclusions: Transfers of fresh embryos on day 5 are superior to those on day 4 and should be favored, especially for people over the age of 40, regardless of the number of embryos transferred, even if that individual has fewer than four oocytes.
8 September 2010 in Journal of Assisted Reproduction and Genetics
Background/Objectives: The timing of blastocyst formation is an important factor in in vitro fertilization (IVF) outcomes. While many studies have shown similar pregnancy rates for euploid blastocyst transfers occurring on day 5 or 6, controversy remains, especially regarding patients with recurrent implantation failure (RIF). This study aimed to evaluate whether day 5 (D5) and day 6 (D6) euploid blastocysts differ in terms of the clinical outcomes achieved after frozen–thawed euploid embryo transfer, with subgroup analysis by maternal age in RIF patients. Methods: This retrospective analysis included a cohort of 514 patients who experienced RIF, categorized into two distinct groups: the initial group consisting of individuals who underwent embryo biopsy on day 5 (n = 456 euploid transfers) and the subsequent group comprising patients who underwent biopsy on day 6 (n = 58 euploid transfers) following ovum retrieval. These groups were utilized based on the completion of blastocyst development and the eventual pregnancy outcomes after the first post-frozen–thawed euploid embryo transfer confirmed by PGT-A. Results: Out of the total cohort of 514 RIF patients, 472 individuals were younger than 40 years of age, representing 91.8% of the sample population. The IVF process yielded successful positive pregnancy outcomes in 85.4% of the cases (439 out of 514)., and there was no statistically significant difference in maternal ages between the day 5 and day 6 biopsy cohorts (p = 0.286). The proportion of successful clinical pregnancies per transfer was markedly higher among those who underwent biopsy on day 5 in comparison to those subjected to biopsy on day 6 (79.2% vs. 58.6%, p = 0.002). In patients aged 35 years and younger who underwent biopsy on day 5, the rates of successful clinical pregnancy outcomes were superior to those who underwent biopsy on day 6 (79.8% vs. 56.5% p = 0.016). In individuals older than 35 years of age, no significant discrepancies in clinical pregnancy rates were observed between the two groups. Conclusions: Day 6 euploid embryo transfer was associated with lower clinical pregnancy rates per transfer compared with those on day 5, particularly in patients younger than 35 years of age. In women ≥ 35 years of age, outcomes did not differ significantly. These outcomes suggest that developmental timing interacts with maternal age in determining clinical outcomes. Further prospective studies with larger and more balanced cohorts are needed to confirm these findings.
Leiomyoma is one of the rarest solid tumours of the ovary. We report a case of a 35 years old woman suffering from irregular menstruel periods and solid unilateral ovarian mass managed by laparoscopic removal. Medical history of the patient is remarkable because of coexisting pelvic kidney and a history of infertility necessiating IVF treatment including gonadotropin stimulation